ArticleNeurology and therapy2022
Patient Experience in Early-Stage Parkinson's Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment.
Article in Neurology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Meaningful digital mobility outcomes for people with Parkinson's disease: Insights grounded in diverse lived experience.Journal of Parkinson's disease · 2026Article
- A Collaborative Approach to Creating Knowledge-Building Resources for the Early-Stage Parkinson's Disease Community.Neurology and therapy · 2026Article
- The Parkinson's Disease-Health Index: A novel, disease-specific patient-reported outcome measure.Journal of Parkinson's disease · 2026Article
- Three years later: tracking bothersome symptoms and impacts for people with early Parkinson's disease.Journal of neurology · 2026Article
- Quantifying the Tolerability of Dopamine Agonist Antiparkinsonian Medication Side Effects: A Best-Worst Scaling Survey.Patient preference and adherence · 2026Article
- Optimizing the MDS-UPDRS Part III for early-stage Parkinson's: early supportive evidence for a limb-related bradykinesia/rigidity sub-score.NPJ Parkinson's disease · 2025Article
- Parkinson's Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation.Cells · 2025Review
- Unlocking the daily impact of parkinson's challenges through a comprehensive assessment using the ChulaPD ADL questionnaire.Scientific reports · 2025Article
- A novel fusion architecture for detecting Parkinson's Disease using semi-supervised speech embeddings.NPJ Parkinson's disease · 2025Article
- Systematic review and consensus conceptual model of meaningful symptoms and functional impacts in early Parkinson's Disease.NPJ Parkinson's disease · 2025Article
- Longitudinal qualitative assessment of meaningful symptoms and relevance of WATCH-PD digital measures for people with early Parkinson's.Journal of neurology · 2025Article
- Including genetic susceptibility towards Parkinson's disease in NAM-based hazard and risk assessment of pesticides: a semi-systematic review.NAM journal · 2025Review
- Understanding what aspects of Parkinson's disease matter most to patients and families.Scientific reports · 2024Article
- An Ethnographic Study of Patient Life Experience in Early-Stage Parkinson's Disease in the United States and Germany.Neurology and therapy · 2024Article
- Article
- Perspectives of People At-Risk on Parkinson's Prevention Research.Journal of Parkinson's disease · 2024Review
- Detecting Parkinson's disease from shoe-mounted accelerometer sensors using convolutional neural networks optimized with modified metaheuristics.PeerJ. Computer science · 2024Article
- Stemming the Tide: The Proactive Role of Allied Health Therapy in Parkinson's Disease.Journal of Parkinson's disease · 2024Review
- The value of co-creating a clinical outcome assessment strategy for clinical trial research: process and lessons learnt.Research involvement and engagement · 2023Article
- Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinson's.Journal of patient-reported outcomes · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionQualitative research on patient experiences in early-stage Parkinson's disease (PD) is limited. It is increasingly acknowledged that clinical outcome assessments used in trials do not fully capture the range of symptoms/impacts that are meaningful to people with early-stage PD. We aimed to conceptualize the patient experience in early-stage PD and identify, from the patient perspective, those cardinal symptoms/impacts which might be more useful to measure in clinical trials.
methodsIn a mixed-methods analysis, 50 people with early-stage PD and nine relatives were interviewed. Study design and results interpretation were led by a multidisciplinary group of patient, clinical, regulatory, and outcome measurements experts, and patient organization representatives. Identification of the cardinal concepts was informed by the relative frequency of reported concepts combined with insights from patient experts and movement disorder specialists.
resultsA conceptual model of the patient experience of early-stage PD was developed. Concept elicitation generated 145 unique concepts mapped across motor and non-motor symptoms, function, and impacts. Bradykinesia/slowness (notably in the form of "functional slowness"), tremor, rigidity/stiffness, mobility (particularly fine motor dexterity and subtle gait abnormalities), fatigue, depression, sleep/dreams, and pain were identified as cardinal in early-stage PD. "Functional slowness" (related to discrete tasks involving the upper limbs, complex mobility tasks, and general activities) was deemed to be more relevant than "difficulty" to patients with early-stage PD, who report being slower at completing tasks rather than encountering significant impairment with task completion.
conclusionPatient experiences in early-stage PD are complex and wide-ranging, and the currently available patient-reported outcome (PRO) instruments do not evaluate many early-stage PD concepts such as functional slowness, fine motor skills, and subtle gait abnormalities. The development of a new PRO instrument, created in conjunction with people with PD, that fully assesses symptoms and the experience of living with early-stage PD, is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.